FDA priority review vouchers granted to three psychedelic developers and a recent executive order may accelerate regulatory timelines for psilocybin and related compounds, with clinical availability potentially within 12 months pending positive Phase 3 data.

Consumer-facing guidance from Verywell Mind highlights how depression in adults over 60 frequently manifests as somatic complaints, cognitive changes, and social withdrawal rather than overt mood symptoms.

VMAT2 inhibitors were associated with lower rates of falls, injuries, fractures, and several secondary adverse outcomes than anticholinergic agents in a propensity-matched cohort of adults with tardive dyskinesia.

A J Clin Psychiatry commentary proposes a risk-benefit matrix favoring empiric catatonia treatment when diagnostic uncertainty exists, citing the syndrome’s high morbidity and the effectiveness of available interventions.

The FDA approved a supplemental NDA adding randomized withdrawal trial data to the lumateperone label, supporting its role in long-term maintenance and relapse prevention in adults with schizophrenia.

CMS finalized a four-code complexity-based structure replacing legacy radiation oncology G-codes effective January 1, 2026, consolidating image guidance and treatment delivery under codes 77387, 77402, 77407, and 77412.